Daxor Corporation announces it will be attending the Annual Scientific Meeting of the Heart Failure Society of America which brings together the world’s leading experts in heart failure at the Huntington Convention Center in Cleveland, Ohio from October 6-9, 2023. Meeting highlights include: New data showing the benefits of blood volume measurement in the ambulatory setting; General session on the value of blood volume measurement in managing congestion; Heart Failure Advisory Board hosted by Daxor; Daxor to attend Corporate Member Meeting with HFSA leadership; Daxor to present products and services in main Exhibit Hall. New data highlighting the applicability of blood volume analysis titled The Value of Blood Volume Analysis to Guide Ambulatory Advanced Heart Failure Care will be highlighted in the e-Poster Hub accompanied by a narrative from the principal investigator, Marc A. Silver, MD, FACP, FACC, FCCP, FAHA, FHFSA.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DXR:
- Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2023
- Daxor Corporation Awarded $305K Grant from the National Institutes of Health to Develop Blood Volume Guidance Software in Sepsis Patients
- Daxor Corporation to Present at the H.C. Wainwright 25th Annual Global Investment Conference
- Daxor reports net assets were $30,359,013 or $6.33 p/s as of June 30
- Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders